Navigation Links
Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
Date:7/8/2008

MAIDENHEAD, England, July 8 /PRNewswire-FirstCall/ --

- PREVENAR Vaccine to Help Protect Children Against the Leading Vaccine-Preventable Cause of Death in Young Children

Wyeth applauds the countries of Cyprus, Hungary, the Kingdom of Bahrain, Republic of Ireland, Slovak Republic and Sweden for announcing their decisions to routinely immunize infants and young children against pneumococcal disease by adding PREVENAR(TM) PCV7 (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed) to their national immunization programs(1). This announcement makes it 24 countries across the world that have now included Prevenar in their immunizations schedules(1).

"We share these countries' commitment to protecting children from the potentially devastating effects of pneumococcal disease and applaud the swift action they have taken in addressing this urgent and pressing health issue," says Bernard Fritzell, Vice President, International Scientific & Clinical Affairs, Wyeth Vaccines Research, in Paris, France. "Wyeth is dedicated to the wellbeing of children and to working with other governments and agencies to further expand the access to Prevenar. This includes accelerating the introduction of the vaccine in those countries that have announced their decision to incorporate Prevenar in their National Immunisation Programmes but have yet to introduce the vaccine as part of their immunization schedule."

This is important news as pneumococcal disease results in 1.6 million deaths per year worldwide, of which up to 1 million deaths are in children younger than five years of age(2). Pneumococcal disease is the leading vaccine-preventable cause of death in children younger than five years of age worldwide(3).

"Specifically, since the introduction of PCV7, into Germany's paediatric immunization schedule in 2006, there has been a 50 percent reduction in vaccine-type invasive pneumococcal disease (IPD) in children younger than 2 years old compared with a pre-vaccine baseline(3). In addition, a slight reduction in vaccine-type IPD among children aged 2-5 years old, an unvaccinated group, also was documented, suggesting a potential "indirect" effect among older children who were not immunized(3). Recent data from Germany, France and the UK highlight the impact of the vaccine in countries where it is part of the national immunization schedule," says Dr Mark van der Linden, Head of the National Reference Center for Streptococci at the Institute of Medical Microbiology, RWTH-Aachen, Germany.

The World Health Organization (WHO) recommends priority inclusion of the 7-valent pneumococcal conjugate vaccine in national childhood immunization programs worldwide due to the significant burden of pneumococcal disease and demonstrated vaccine efficac(6). Recently, the Strategic Advisory Group of Experts (SAGE) to WHO issued a preliminary recommendation that pneumococcal disease prevention be ranked as a very high priority on a global basis(6).

PREVENAR, the only licensed pneumococcal conjugate vaccine, is now available in 88 countries around the world, with more than 180 million doses distributed(1).

Pneumococcal Disease

Pneumococcal disease affects both children and adults and is a leading cause of illness and death worldwide(6). Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae and describes a group of illnesses, including invasive infections, such as bacteremia/sepsis and meningitis, as well as pneumonia and upper respiratory tract infections, including otitis media(7). PREVENAR is the first and only pneumococcal conjugate vaccine approved to help protect infants and young children against pneumococcal disease caused by the serotypes included in the vaccine(7).

References available on request.

Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
2. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
3. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
4. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
5. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
6. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
9. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
10. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Wells Specialty Pharmacy announces the acquisitions and merger ... Winter Park, Florida and Pharm-EZ Medical, ... have been consolidated into the 3796 Howell Branch Road Facility. ... that Chad Tomlinson , former Vice President of Operations, ... Mr. Tomlinson is a Graduate of Florida State University and ...
(Date:1/19/2017)... 2017 Report Details What can ... are going to grow at the fastest rates? This ... data, trends, opportunities and prospects. Our 190-page report ... lucrative areas in the industry and the future market ... across the all the major categories of the ophthalmic ...
(Date:1/19/2017)... This report on the opioid induced constipation ... the global market. Large number of chronic pain sufferers ... is a major side effect of consumption of opioid ... therapy has been prescribed to treat opioid induced constipation. ... and growing awareness about the therapy are the major ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account ... Word: Chocolate Biscuit” is the creation of published author, Marlyn Ivey, born in Lynn Haven, ... he went to school and at 19 years of age, he joined the Navy and ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study indicating superior ... MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure Devices During ...
(Date:1/20/2017)... ... ... to Christmas:” a beautiful and enchanting tale that teaches children the true meaning of Christmas. ... in Oklahoma City, and a devoted woman of faith. , “Becoming a parent changes ... back of my mind for years, but actually doing it might have been a while ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “The Land ... brings attention to the issue of world hunger, and shares the simple and achievable ... Brubaker, devoted husband and member of the Fairview Missionary Church in Angola, Indiana where ...
(Date:1/19/2017)... ... January 20, 2017 , ... Today, the Centers for Medicare & Medicaid ... CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who participate in APMs are paid ... important part of the Administration’s effort to build a system that delivers better care ...
Breaking Medicine News(10 mins):